# Therapeutic Vaccine for HIV

> **NCT01859325** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 33 (actual)

## Conditions studied

- HIV
- Therapeutic Vaccine

## Interventions

- **BIOLOGICAL:** rVSV
- **BIOLOGICAL:** IL-12 pDNA adjuvant
- **BIOLOGICAL:** HIV-Mag pDNA
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01859325
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05-10
- **Primary completion:** 2017-02-26
- **Final completion:** 2017-02-26
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2020-03-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01859325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01859325, "Therapeutic Vaccine for HIV". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01859325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*